Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation.
There is limited experience on engraftment syndrome (ES) in children. The present study analyzes the characteristics of ES in pediatric patients undergoing autologous peripheral blood progenitor cells transplantation (PBPCT). From 1993 to 2001, 30 of 156 patients (19.2%) who underwent PBPCT developed ES (skin rash which involved more than 27% of the body surface and temperature >38.3 degrees C with no compatible infectious disease etiology, during neutrophil recovery). Of the 30 patients who developed ES, 20 (66%) developed hypoxia and/or pulmonary infiltrates, seven (23%) had hepatic dysfunction, six (20%) developed renal insufficiency, 16 (53%) showed weight gain and three (10%) experienced transient encephalopathy. Multivariate analysis showed that the only positive predictive factor for developing ES was mobilization with high-dose G-CSF (12 microg/kg twice daily) (RR 3.88, CI 95% 1.73-8.67; P < 0.0005). The overall transplant-related mortality (TRM) was 8.33% and this was significantly higher in the patients who developed ES than in those who did not (23% vs 4.76%; P < 0.0001). We also found a higher morbidity in patients who developed ES, expressed as a statistically significant increase in supportive care (transfusion requirement, parenteral nutrition) and increase in the length of hospital stay. In summary, we have found ES to be the most important cause of morbidity and mortality in children undergoing autologous PBPCT.
Madero
L
L
Department of Pediatric Hematology and Oncology, Hospital Infantil Niño Jesús, Madrid, Spain.
Vicent
M G
MG
Sevilla
J
J
Prudencio
M
M
Rodríguez
F
F
Díaz
M A
MA
D000293:Adolescent; D002423:Cause of Death; D002648:Child; D002675:Child, Preschool; D005076:Exanthema / Q000209:etiology*; D005260:Female; D005334:Fever / Q000209:etiology*; D006085:Graft Survival / Q000502:physiology*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000633:toxicity; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000401:mortality; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000401:mortality / Q000628:therapy; D009504:Neutrophils / Q000166:cytology; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D013577:Syndrome; D014182:Transplantation, Autologous
D016179:Granulocyte Colony-Stimulating Factor